Status | Study |
Active, not recruiting |
Study Name: Investigation of Immune Disorders and Deficiencies Condition: Primary Immune Deficiencies Autoimmune Diseases Inflammato Date: 2013-05-06 |
Recruiting |
Study Name: Immune Disorder HSCT Protocol Condition: Immune Deficiency Disorders Severe Combined Immunodeficiency Date: 2013-03-19 Interventions: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan Between days - |
Completed |
Study Name: Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Condition: Primary Immunodeficiency Agammaglobulinemia Date: 2012-04-16 Interventions: Biological: Kedrion IVIG 10% Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 t |
Recruiting |
Study Name: EZN-2279 in Patients With ADA-SCID Condition: ADA-SCID Adenosine Deaminase Deficiency Severe Combined Im Date: 2011-08-18 Interventions: Biological: EZN-2279 weekly ad |
Recruiting |
Study Name: Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency Condition: Adenosine Deaminase Deficiency Severe Combined Immunodeficiencies (SCID) Date: 2011-06-23 Interventions: Genetic: EF1αS-ADA lentiviral vector transduced patient Cd34+ cells EF1αS-ADA lentiviral vecto |
Completed |
Study Name: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Condition: Primary Immune Deficiency Disorders Common Variable Immunodeficiency Date: 2011-01-27 Interventions: Biological: Gammaplex GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intraveno |
Completed |
Study Name: Gene Therapy ADA Deficiency Condition: Adenosine Deaminase Deficiency Date: 2011-01-18 Interventions: Biological: Intravenous infusion of transduced cells Intravenous infusion of transduced cells |
Withdrawn |
Study Name: Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents Condition: ADA-SCID Date: 2010-08-14 |
Recruiting |
Study Name: A Phase I Study of Mozobil in the Treatment of Patients With WHIMS Condition: WHIMS Neutrophil Disorder Myelokathexis Date: 2009-08-27 Interventions: Drug: Mozobil (TM) |
Completed |
Study Name: Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin Condition: Common Variable Immunodeficiency Agammaglobulinemia Date: 2008-04-14 Interventions: Biological: gammaglobulin They were administered a polyvalent, pasteurized liquid immune globulin subcut |